The U.S. Food and Drug Administration (FDA) has designated Insulet Corp.’s PODD recall of certain Omnipod insulin delivery ...

Left unable to speak or walk after a malfunction, the 50-year-old feels the vulnerabilities in this technology needs to be ...

Insulet’s wearable insulin patch Omnipod may be able to seamlessly control insulin delivery for patients with diabetes, but ...

July 17, 2026) - Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities between ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results ...

A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain ...

“Since its commercial launch in the United States, Omnipod 5 has had a remarkable impact on people with diabetes,” said Jim Hollingshead, Insulet President and CEO. “Every day, we hear how this ...

Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked ...

PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod ...